Merck KGaA’s Strategic SpringWorks Acquisition Yields Key European Approvals

Merck KGaA’s recent $3.9 billion acquisition of SpringWorks Therapeutics is demonstrating immediate strategic value, with European regulators granting marketing authorization for two key therapies that significantly bolster the company’s presence in the rare disease market.

European Regulatory Milestones Achieved

The European Commission granted approval on August 18, 2025, for OGSIVEO® (nirogacestat) as a treatment for adults with progressing desmoid tumors. This decision followed the conditional marketing authorization awarded on July 18, 2025, for EZMEKLY® (mirdametinib) targeting neurofibromatosis type 1-associated plexiform neurofibromas in patients aged two years and older.

These regulatory successes stem from positive assessments issued by the European Medicines Agency’s CHMP committee in May and June of 2025. Both therapeutic options had previously received approval from the U.S. Food and Drug Administration.

Strategic Expansion Through Acquisition

The July 2025 acquisition, which resulted in the delisting of SpringWorks shares, immediately enhances Merck KGaA’s healthcare division with:

Should investors sell immediately? Or is it worth buying SpringWorks Therapeutics?

• OGSIVEO®: The first systemic therapy option for aggressive desmoid tumors
• EZMEKLY®: The only approved treatment specifically for NF1-PN
• Market Access: European approvals open significant new commercial territories

This strategic move specifically strengthens the Darmstadt-based company’s capabilities in rare oncology conditions while substantially expanding its commercial footprint in the United States.

Commercialization Phase Commences

With European regulatory hurdles cleared, Merck KGaA now enters the critical commercialization phase for both therapies. These treatments address areas of significant unmet medical need and are positioned to contribute immediately to the company’s revenue stream.

The company anticipates a measurable financial impact from these products by 2027. The expanded pipeline within Merck KGaA’s oncology and rare disease division will benefit from the corporation’s substantial resources and global infrastructure for further development.